Background: The role of uric acid in development of renal dysfunction (RD) remains controversial. Earlier studies have reported inconsistent results, possibly because of their varying ability to adjust for confounding. The impact of longitudinal change in uric acid on renal outcome has not been assessed previously. We aimed to study the impact of change in serum uric acid (SUA) as well as baseline SUA on the development of RD.
Methods: In a prospective cohort study, we assessed the associations between change in SUA during follow-up, baseline SUA and RD (defined as albumin-creatinine-ratio (ACR) ≥1.13 mg albumin/mmol creatinine and/or eGFR < 60 ml/min/1.73 m(2)) in a large cohort from a general population participating in the Tromsø Study (n = 2637). Participants were stratified according to tertiles of change in SUA between baseline (1994/95) and follow-up 13 years later. (upper tertile: SUA increasing group, two lower tertiles: SUA non-increasing group). Logistic regression analysis was applied with RD and each component of RD after 7 and 13 years as the dependent variables. Adjustments were made for baseline eGFR, cardiovascular risk factors, and the use of antihypertensive drugs including diuretics.
Results: After excluding participants with RD at baseline, SUA increasers, compared to SUA non-increasers, had a doubled risk of RD after 7 years (odds ratio 2.00, (95 % CI 1.45, 2.75)). Odds ratio for RD in SUA increasers after 13 years was 2.18 (95 % CI 1.71, 2.79). The risk of developing ACR ≥1.13 mg/mmol alone was not significantly increased after 7 years (odds ratio 1.30 (95 % CI 0.90, 1.89), but after 13 years (odds ratio 1.43 (95 % CI 1.09, 1.86)). An increase in baseline SUA of 59 μmol/L (1 mg/dL) gave an odds ratio for RD after 13 years of 1.16 (95 % CI 1.04, 1.29).
Conclusion: An increase in SUA during follow-up was associated with an increased risk of developing RD after 7 and 13 years.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676817 | PMC |
| http://dx.doi.org/10.1186/s12882-015-0207-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
hURAT1 Transgenic Mouse Model for Evaluating Targeted Urate-Lowering Agents.
Int J Rheum Dis
January 2025
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Background: Urate transporter 1 (URAT1) is a well-known therapeutic target for reducing urate levels in the treatment of hyperuricemia and gout. However, current pharmacological studies have failed to evaluate the efficacy of URAT1 inhibitors in non-primate animal models. We established a human URAT1 (hURAT1) transgenic knock-in (KI) mouse model to assess uricosuric agents' effectiveness and characterize URAT1-caused pathogenesis.
View Article and Find Full Text PDFExploring the relationship between the uric acid to high-density lipoprotein cholesterol ratio and depression: a cross-sectional study from NHANES.
Sci Rep
December 2024
First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, 150040, China.
Depression is one of the most burdensome diseases worldwide, garnering significant attention. The uric acid to high-density lipoprotein cholesterol ratio (UHR) is a novel and easily obtainable indicator used to assess the body's inflammatory and metabolic status. It has attracted interest due to its potential role in the prevention and treatment of depression.
View Article and Find Full Text PDFPathological, hematological, and biochemical alteration in broiler chickens infected with mycotoxin in Babylon province.
Open Vet J
November 2024
Directorate of Veterinary Medicine, Babylon, Iraq.
Background: Mycotoxins are considered one of the most important problems and threats that face poultry producers.
Aim: This study was conducted to investigate the pathological, hematological, and biochemical alterations in chickens fed on mycotoxins contamination ration.
Methods: 434 feed samples were collected from poultry farms operating in Babil Governorate/Iraq, where feed samples were collected over the course of 2023, and these samples were tested by direct competitive enzyme-linked immunosorbent assay to determine the level of mycotoxins.
Diagnostic approach to heart failure in Türkiye.
Turk J Med Sci
December 2024
Department of Cardiology, Faculty of Medicine, Mersin University, Mersin, Turkiye.
Background/aim: Final diagnosis of heart failure (HF) relies on a combination clinical findings, laboratory and imaging tests. The aim of this study was to review the diagnostic approach to HF in Türkiye.
Materials And Methods: This study is a subanalysis of the nationwide TRends-HF study, based on anonymized data from National Electronic Database between January 1, 2016, and December 31, 2022.
Development and verification of a nomogram for recurrence risk of Benign Paroxysmal Positional Vertigo in middle-aged and older populations.
Front Neurol
December 2024
Department of Neurology, First Hospital of Changsha, Changsha, China.
Background: Benign Paroxysmal Positional Vertigo (BPPV) is the most common cause of peripheral vertigo, with frequent recurrence, particularly pronounced among middle-aged and elderly populations, significantly affecting patients' quality of life. This study aimed to identify predictive factors for recurrence in middle-aged and older patients with BPPV and to develop a nomogram prediction model based on these predictors.
Methods: This retrospective study included 582 participants aged ≥45 years who were selected from the electronic medical records system of the First Hospital of Changsha between March 2021 and March 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!